Assessment of risk factors for bone disease in renal transplant recipients

Journal of Pharmacy Technology

Volumn 18, Issue 2, 2002, Pages 54-62

  Joy, Melanie S ^a   Hollar, Kimberly D ^a   Neyhart, Clara D ^a   Hogan, Susan L ^a   Dupuis, Robert E ^a   Finn, William F ^a   Dooley, Mary Anne ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; CREATININE; CYCLOSPORIN; HEPARIN; LEVOTHYROXINE; LITHIUM; LOOP DIURETIC AGENT; PARATHYROID HORMONE; PHENYTOIN; PHOSPHORUS; TACROLIMUS; VITAMIN D;

ADULT; ARTICLE; BODY WEIGHT; BONE ATROPHY; BONE DENSITY; BONE DISEASE; BONE MINERAL; CLINICAL ARTICLE; CREATININE CLEARANCE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MALE; PHYSICAL ACTIVITY; RISK FACTOR;

EID: 0036227928     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250201800202     Document Type: Article

References (42)

1. Diagnosis, prophylaxis, and treatment of osteoporosis
2. Interim report and recommendations of the World Health Organization task-force for osteoporosis
3. Intestinal calcium absorption in exogenous hypercortisolism: Role of 25-hydroxyvitamin D and corticosteroid dose
4. Reduction in serum testosterone levels during chronic glucocorticoid therapy
5. Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells
6. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss
7. Testosterone therapy in glucocorticoid-treated men
8. Glucocorticoids decrease vitamin D receptor number and gene expression in human osteosarcoma cells
9. Influence of vitamin D receptor genotype on bone mass changes after renal transplantation
10. Cortisol inhibits the synthesis of insulin-like growth factor-I in skeletal cells
11. Steroid-induced fractures and bone loss in patients with asthma
12. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis
13. Effect of inhaled corticosteroids on bone
14. Bone loss in adults receiving alternate day glucocorticoid therapy: A comparison with daily therapy
15. The diagnosis of osteoporosis
16. High blood pressure and bone-mineral loss in elderly white women: A prospective study
17. Osteoporosis and osteomalacia
18. Combined treatment with cyclosporin A and cortisone acetate minimizes the adverse bone effects of either agent alone
19. The deleterious effects of long-term cyclosporin A, cyclosporin G, and FK506 on bone mineral metabolism in vivo
20. Osteoporosis after organ transplantation
21. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation
22. Long-term bone loss in kidney transplant recipients: A cross-sectional and longitudinal study
23. Bone loss after kidney transplantation: A longitudinal study in 115 graft recipients
24. Osteoporosis after renal transplantation: Single center experience
25. Posttransplant bone disease: Evidence for a high bone resorption state
26. Bone disease in patients with long-term renal transplantation and normal renal function
27. Loss of regional bone mineral density in the first 12 months following renal transplantation
28. Rapid loss of vertebral mineral density after renal transplantation
29. Changes in bone mass early after kidney transplantation
30. Clinical utility of bone mass measurement in adults: Consensus of an international panel
31. 3 supplementation prevents bone loss in spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial
32. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy
33. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin
34. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
35. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss
36. Treatment of established bone loss after renal transplantation with etidronate
37. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
38. Intravenous pamidronate (APD) prevents corticosteroid induced bone loss: A prospective controlled study
39. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: A two year follow up study
40. A multidisciplinary renal clinic for corticosteroid-induced bone disease
41. Increased risk of fracture in patients receiving solid organ transplants